Organization
Cellular Therapy
1 abstract
Abstract
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,